泽夫拉治疗
ZVRA
9.94
-0.33
-3.21%
泽夫拉治疗
US · ZVRA
#3562 按市值排名
9.94
-0.33
-3.21%
实时 - 追踪5344个代码 - 心跳于328秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例下降了3.4个百分点。
机构持股
- 机构持股比例
- 77.23% -3.41pp
- 机构数量
- 192 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund52.84%
Hedge Fund19.27%
Public Company3.10%
Private Company1.46%
Individual/Insider1.17%
Insurance Company0.24%
Government Pension Fund0.21%
Family Office/Trust0.11%
Other21.60%
主要股东 截至 2026-06-30
BlackRock
8.60% · 5.11M 股
FMR
8.28% · 4.92M 股
Woodline Partners LP
8.06% · 4.79M 股
Vanguard Capital Management, LLC
5.12% · 3.04M 股
Nantahala Capital Management, LLC
3.03% · 1.80M 股
State Street Global Advisors
2.83% · 1.68M 股
Geode Capital Management, LLC
2.59% · 1.54M 股
D. E. Shaw & Co., L.P.
2.20% · 1.31M 股
Qube Research & Technologies Ltd
2.09% · 1.24M 股
Legal & General Investment Management
2.02% · 1.20M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 33次买入 · 17次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Neil McFarlane | Chief Executive Officer | 0.65% |
| John Bode | Independent Director | 0.21% |
| Joshua Schafer | Chief Commercial Officer & Executive VP of Business Development | 0.10% |
| Rahsaan Thompson | Chief Legal Officer, Secretary & Compliance Officer | 0.06% |
| Timothy Sangiovanni | Officer | 0.05% |
| Thomas Anderson | Director | 0.03% |
| Alvin Shih | Director | 0.03% |
| Adrian Quartel | Chief Medical Officer | 0.02% |
| Tamara Favorito | Independent Chairperson | 0.01% |
| Corey Watton | Independent Director | 0.00% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-13 | Rahsaan Thompson | Chief Legal Officer, Secretary & Compliance Officer | Automatic Disposition | -42,666 | $11.13 |
| 2026-08-09 | Corey Watton | Independent Director | Derivative Exercise and Sale | -12,300 | $4.97–11.25 |
| 2026-06-21 | Rahsaan Thompson | Chief Legal Officer, Secretary & Compliance Officer | Derivative Exercise and Sale | -34,557 | $12.68 |
| 2026-06-20 | Rahsaan Thompson | Chief Legal Officer, Secretary & Compliance Officer | Derivative Exercise and Retained | +32,110 | -- |
| 2026-06-03 | Douglas Calder | Independent Director | Other Derivative Acquisition | +30,000 | $11.17 |
| 2026-06-03 | Tamara Favorito | Independent Chairperson | Other Derivative Acquisition | +30,000 | $11.17 |
| 2026-06-03 | Corey Watton | Independent Director | Other Derivative Acquisition | +30,000 | $11.17 |
| 2026-06-03 | Alicia Secor | Director | Other Derivative Acquisition | +30,000 | $11.17 |
| 2026-06-03 | Thomas Anderson | Director | Other Derivative Acquisition | +30,000 | $11.17 |
| 2026-06-03 | Alvin Shih | Director | Other Derivative Acquisition | +30,000 | $11.17 |
| 2026-05-27 | Timothy Sangiovanni | Officer | Other Derivative Acquisition | +20,000 | -- |
| 2026-05-27 | Timothy Sangiovanni | Officer | Other Derivative Acquisition | +40,000 | $11.40 |
| 2026-05-10 | Rahsaan Thompson | Chief Legal Officer, Secretary & Compliance Officer | Automatic Disposition | -1,794 | $11.30 |
| 2026-03-23 | John Bode | Independent Director | Derivative Exercise and Retained | +78,400 | $4.89–4.97 |
| 2026-03-17 | Justin Renz | Chief Financial Officer | Other Derivative Acquisition | +300,000 | $9.55 |
| 2026-02-08 | Neil McFarlane | Chief Executive Officer | Derivative Exercise and Sale | -14,625 | $8.56 |
| 2026-02-06 | Neil McFarlane | Chief Executive Officer | Derivative Exercise and Retained | +22,875 | -- |
| 2026-02-02 | Timothy Sangiovanni | Officer | Automatic Disposition | -3,000 | $9.18 |
| 2026-02-02 | Joshua Schafer | Chief Commercial Officer & Executive VP of Business Development | Automatic Disposition | -10,500 | $9.19 |
| 2026-02-01 | Neil McFarlane | Chief Executive Officer | Derivative Exercise and Sale | -91,000 | $9.38 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
泽夫拉治疗 讨论区 0 条评论